JP2001502299A5 - - Google Patents

Download PDF

Info

Publication number
JP2001502299A5
JP2001502299A5 JP1998513398A JP51339898A JP2001502299A5 JP 2001502299 A5 JP2001502299 A5 JP 2001502299A5 JP 1998513398 A JP1998513398 A JP 1998513398A JP 51339898 A JP51339898 A JP 51339898A JP 2001502299 A5 JP2001502299 A5 JP 2001502299A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998513398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001502299A (ja
Filing date
Publication date
Priority claimed from GBGB9619172.1A external-priority patent/GB9619172D0/en
Priority claimed from GBGB9625917.1A external-priority patent/GB9625917D0/en
Priority claimed from GBGB9713994.3A external-priority patent/GB9713994D0/en
Application filed filed Critical
Priority claimed from PCT/GB1997/002490 external-priority patent/WO1998010748A1/en
Publication of JP2001502299A publication Critical patent/JP2001502299A/ja
Publication of JP2001502299A5 publication Critical patent/JP2001502299A5/ja
Ceased legal-status Critical Current

Links

JP10513398A 1996-09-13 1997-09-15 リポソーム Ceased JP2001502299A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9619172.1A GB9619172D0 (en) 1996-09-13 1996-09-13 Liposomes
GBGB9625917.1A GB9625917D0 (en) 1996-12-13 1996-12-13 Liposomes
GB9625917.1 1997-07-01
GB9619172.1 1997-07-01
GBGB9713994.3A GB9713994D0 (en) 1997-07-01 1997-07-01 Liposomes
GB9713994.3 1997-07-01
PCT/GB1997/002490 WO1998010748A1 (en) 1996-09-13 1997-09-15 Liposomes

Publications (2)

Publication Number Publication Date
JP2001502299A JP2001502299A (ja) 2001-02-20
JP2001502299A5 true JP2001502299A5 (enExample) 2005-09-08

Family

ID=27268476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10513398A Ceased JP2001502299A (ja) 1996-09-13 1997-09-15 リポソーム

Country Status (11)

Country Link
US (1) US7790696B2 (enExample)
EP (2) EP1254657B1 (enExample)
JP (1) JP2001502299A (enExample)
KR (1) KR100507660B1 (enExample)
CN (1) CN1138533C (enExample)
AT (2) ATE228824T1 (enExample)
AU (1) AU728581B2 (enExample)
CA (1) CA2271388C (enExample)
DE (2) DE69717661T2 (enExample)
ES (2) ES2187812T3 (enExample)
WO (1) WO1998010748A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146907A2 (en) * 1999-02-05 2001-10-24 Genzyme Corporation Use of cationic lipids to generate anti-tumor immunity
CN1137723C (zh) * 1999-06-22 2004-02-11 研究发展基金会 强化的用于加速伤口愈合的伤口覆盖物和组合物
KR100744237B1 (ko) * 1999-10-01 2007-07-30 리폭센 테크놀로지즈 리미티드 리포솜-포획된 디엔에이 경구용 백신
US7381421B2 (en) 1999-12-13 2008-06-03 Lipoxen Technologies Limited Liposomes
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
AU2003244855A1 (en) 2002-07-05 2004-01-23 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
JP4546115B2 (ja) * 2004-03-05 2010-09-15 三菱化学メディエンス株式会社 細胞中ａｔｐの定量法
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
CN100400667C (zh) * 2006-06-27 2008-07-09 浙江大学 脂质体包裹弓形虫pGRA4真核表达质粒的方法及用途
US8753878B2 (en) 2006-12-22 2014-06-17 Ewos S.A. Process and formulation for immunizing fish in aquaculture systems
RU2367443C1 (ru) * 2008-02-28 2009-09-20 Общество с ограниченной ответственностью "Битеп" Средство на основе природных фосфолипидов
EP2184054A1 (en) 2008-11-08 2010-05-12 Lipoxen Technologies Limited Small Interfering RNA Delivery
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
ME03091B (me) 2009-12-01 2019-01-20 Translate Bio Inc Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima
US9408914B2 (en) * 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
DK2590676T3 (en) 2010-07-06 2016-10-24 Glaxosmithkline Biologicals Sa Virionlignende feed particles to self-replicating RNA molecules
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
RU2491062C2 (ru) * 2011-03-16 2013-08-27 Общество С Ограниченной Ответственностью "Биотехнологии Пущино" Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий
HRP20250981T1 (hr) 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
EP3456316A1 (en) 2011-07-06 2019-03-20 GlaxoSmithKline Biologicals S.A. Cationic oil-in-water emulsions
CN103781470A (zh) 2011-07-06 2014-05-07 诺华股份有限公司 包含核酸的水包油乳液
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
BR112014030677A2 (pt) 2012-06-08 2022-07-19 Shire Human Genetic Therapies distribuição pulmonar de mrna para células-alvo não-pulmonares
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
CA2904151C (en) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
KR20150128687A (ko) 2013-03-14 2015-11-18 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 정제 방법
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
EA201992208A1 (ru) 2013-10-22 2020-07-31 Транслейт Био, Инк. ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
WO2015100269A2 (en) * 2013-12-27 2015-07-02 Double Helix Corporation Compositions and methods for providing active telomerase to cells in vivo
EP3094345B1 (en) * 2014-01-17 2018-03-14 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Liposome-based immunotherapy
KR102739894B1 (ko) 2014-04-25 2024-12-05 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
US20220333178A1 (en) 2021-03-22 2022-10-20 Illumina Cambridge Limited Methods for improving nucleic acid cluster clonality

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
EP0172007B1 (en) 1984-08-10 1991-05-22 Syntex (U.S.A.) Inc. Stable liposomes with aqueous-soluble medicaments and methods for their preparation
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5208036A (en) * 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
NZ214716A (en) 1985-01-07 1989-04-26 Syntex Inc 1,2-dialkoxy-omega-trialkylammonium cationic surfactants
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) * 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
JP2627899B2 (ja) * 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
US4882172A (en) * 1988-04-08 1989-11-21 Nabisco Brands, Inc. System for processing chewing gum
JP2923296B2 (ja) * 1988-11-14 1999-07-26 株式会社ビタミン研究所 細胞への遺伝子導入法
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) * 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
CA2128616A1 (en) 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
EP0713388B1 (en) * 1993-08-06 1999-05-06 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
ES2115343T3 (es) * 1993-11-05 1998-06-16 Amgen Inc Metodo de preparacion de liposomas y encapsulacion de material.
DK0729351T3 (da) * 1993-11-16 2000-10-16 Skyepharma Inc Vesikler med reguleret afgivelse af aktivstoffer
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
ATE285477T1 (de) * 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5753235A (en) * 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
US7384923B2 (en) * 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000515496A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2001503573A5 (enExample)
JP2000503303A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2001502299A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2001504113A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000511955A5 (enExample)
JP2000505356A5 (enExample)
JP2000508653A5 (enExample)
JP2001505352A5 (enExample)
JP2000501744A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)